QNRX News and Press, Quoin Pharmaceuticals Ltd. From 05/24/23

ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treat...

2023-05-12 16:43:09 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman, Chief Executive Officer and Director Conference...

2023-05-08 17:04:33 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q1 GAAP EPS of -$0.34 misses by $0.06 . For further details see: Quoin Pharmaceuticals GAAP EPS of -$0.34 misses by $0.06

First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome ...

ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its first qua...

ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open la...

2023-03-09 14:27:02 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Conference Call March 9, 2023 08:30 ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Conference Call Participants James Molloy ...

2023-03-08 17:19:48 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q4 GAAP EPS of -$0.41 beats by $0.19 . For further details see: Quoin Pharmaceuticals GAAP EPS of -$0.41 beats by $0.19

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy Continued adv...

ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 f...